secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2024-10-10T23:59:59+00:00
Accession:  0000950170-24-113963
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kezar receives unsolicited $1.10/share acquisition proposal from Concentra Biosciences
--------------------------------------------------------------------------------

- Concentra offers $1.10 per share plus a contingent value right for 80% of net proceeds from out-licensing or disposition of Kezar's programs.
- Tang Capital Management, which beneficially owns ~9.9% of Kezar, is Concentra's controlling stockholder.
- Kezar's Board will evaluate the non-binding proposal to determine the best course for stockholders; no immediate action required.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000095017024113963/0000950170-24-113963-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000095017024113963/kzr-20241010.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-113963

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer